Pregnancy
UK drugs regulator warns women on weight loss jabs must use contraception amid ‘Ozempic baby boom’
Women using weight loss injections have been advised to use reliable contraception after the UK’s medicines regulator received 40 reports of pregnancies—some of them unexpected, despite birth control.
As reported by Sky News, the Medicines and Healthcare products Regulatory Agency (MHRA) has issued a public safety alert about GLP-1 receptor agonists—including Ozempic, Wegovy, Mounjaro, Saxenda, and Victoza—warning that these drugs should not be taken during pregnancy, while trying to conceive, or while breastfeeding.
The MHRA revealed it had received 26 pregnancy-related reports involving Mounjaro, including one from a woman who said the pregnancy was unplanned.
A further eight reports involved Ozempic or Wegovy, and nine were linked to Saxenda or Victoza, with one woman stating her pregnancy was accidental.
GLP-1 drugs work by mimicking a hormone released after eating that helps people feel full. Mounjaro also targets a second hormone linked to appetite and blood sugar regulation.
The agency stated there is currently insufficient safety data to determine if these drugs could harm a developing baby.
Women are advised to stop taking them immediately if they become pregnant and to discontinue use for two months before attempting to conceive.
Mounjaro has also been found to reduce the effectiveness of oral contraceptives in individuals who are overweight.
The MHRA recommends that those taking Mounjaro who are overweight and using an oral form of contraception should also use a non-oral form of contraception.
This is especially important during the first four weeks after starting Mounjaro and after any dose increase.
Dr Alison Cave, chief safety officer at the MHRA, said: “These medicines are licensed to treat specific health conditions — they are not cosmetic products.
“They are not a quick fix for weight loss and have not been assessed for safety when used in this way.”
The drugs have been associated with what some are calling an “Ozempic baby boom” or “Mounjaro babies”—unexpected pregnancies among women taking contraception.
The MHRA advised that effective contraception includes oral contraceptives, implants, intrauterine devices (coils), and condoms.
For Mounjaro users who are overweight, non-oral methods are especially recommended due to potential interference with the pill.
The agency also reminded patients to watch for symptoms of acute pancreatitis—an uncommon but serious side effect.
This includes severe stomach pain that spreads to the back and doesn’t ease, which should be treated as a medical emergency.
Jasmine Shah, medication safety officer at the National Pharmacy Association, said: “Pharmacists urge women taking GLP-1 medicines to take note of this new guidance and to use effective contraception.
“Community pharmacies are seeing unprecedented demand for weight loss injections.
“It’s essential that safety guidance keeps up with this trend, and that patient wellbeing remains our priority.”
The MHRA also reiterated warnings about purchasing weight loss drugs from unregulated sources such as social media or beauty salons, where products may be fake or dangerous.
“Any suspected side effects or counterfeit products should be reported through the Yellow Card scheme.
Shah added: “We strongly echo the MHRA’s advice to avoid potentially fake weight loss jabs sold online or in salons, which could seriously harm health.
“Anyone with concerns about these medications should speak to their pharmacist.”
Pregnant women are among the first groups offered the NHS flu vaccine this winter, which has been updated to better match the subclade K strain.
Schoolchildren are also being prioritised and, like pregnant women, can receive the vaccine from September because they can catch and spread flu easily.
Protecting them also helps others, including younger siblings and grandparents.
Other eligible groups, including people aged 65 and over, will be able to receive a free NHS flu vaccine from October and should receive an invitation by phone or post.
Dr Amanda Doyle from NHS England said: “Last year’s flu season came early and was made worse by a new variant, which had a major impact for patients and put enormous pressure on urgent and emergency care services across the country.
“With the NHS experiencing its busiest summer on record, staff have started preparing for this winter earlier than ever – and with services already under significant pressure, it is vital that everyone offered the vaccine comes forward.”
Last winter’s flu season began more than a month earlier than usual as a new mutated strain circulated.
The strain was sometimes referred to as “Super flu”, although this is not a medical term and does not mean the virus is harder to treat. The name reflected that people had yet to build up immunity against it.
Flu vaccines are updated each year to better match the influenza viruses expected to circulate. These viruses continually mutate, so experts must predict how they are likely to change.
This winter’s vaccine includes changes intended to provide a better match for subclade K.
It remains unclear when flu will begin circulating widely this winter or how severe the season will be. Experts often look at flu activity in southern hemisphere countries such as Australia and New Zealand for indications of how the UK season could develop.
Their flu season peaks in July or August. Australia has recorded fewer cases than last year, while New Zealand has experienced high numbers.
Everyone is at risk of catching flu, regardless of age or how fit and healthy they are.
Doyle said: “Flu can really knock you for six, and for some children and pregnant women it can mean becoming seriously ill or ending up in hospital.”
The flu vaccine cannot give you flu. Instead, it helps the body know how to fight the virus.
Children aged two and over receive a nasal spray version, while adults receive an injection. One dose is needed ahead of winter.
Free NHS flu vaccines are available through pharmacies, GPs and schools. People who are not eligible for a free vaccination can pay around £10 to £20.
Schoolchildren and pregnant women can receive a free NHS flu vaccine from September onwards.
From October, free vaccination will also be available to children aged two or older who have not yet started school, people aged 65 and over, those with certain long-term health conditions, care home residents and carers of older or disabled people, including those receiving a carer’s allowance.
It will also be available to people living with someone who has a weakened immune system and those experiencing homelessness or staying in a homeless hostel or night shelter.
More adults will also be offered vaccination against respiratory syncytial virus (RSV), a virus that attacks the lungs, this winter.
From September, adults with certain pre-existing health conditions, such as chronic lung disease, will be invited for the RSV vaccine when they turn 65 rather than waiting until 75.
Four leading cardiovascular health groups have agreed new guidance for healthcare professionals assessing patients with suspected heart attacks.
Historically, some less common forms of heart attack, which evidence shows affect women far more than men, have been classified as less important, with treatment and care often worse as a result.
Experts said women had been receiving less effective treatments that did not always target the specific cause of their heart attack and could even make them more unwell.
The changes were announced in Munich on the opening day of the annual congress of the European Society of Cardiology (ESC).
Professor Bryan Williams, chief scientific and medical officer of the British Heart Foundation, said: “This is a landmark moment, a radical shift in how we define and diagnose heart attacks worldwide which will transform people’s care.
“For decades, women have missed out on accurate diagnoses and treatment.
“This focus on finding less common causes of heart attacks, which predominantly affect women, should help to change that. It could be life-changing for huge numbers of women in the UK and worldwide.”
The new guidance upgrades three types of heart attack that can be up to 10 times more common in women and are often caused by childbirth, exercise and emotional stress.
The most serious cases, previously known as “type 1” and now classed as “primary” heart attacks, had previously prioritised those caused by a clot blocking blood flow to the heart.
Other forms can involve reduced blood flow for different reasons, including the tightening or tearing of coronary arteries. These can be more likely to be missed or treated less urgently.
The guidance also introduces a lower diagnostic threshold for women based on levels of troponin, a protein released into the blood when the heart is injured and damaged.
Previously, women were expected to meet the same troponin threshold as men to receive a diagnosis.
Williams said the streamlined heart attack categories would also help patients understand the cause of their heart attack and what comes next.
The three upgraded types are coronary artery spasm, coronary embolism and spontaneous coronary artery dissection (SCAD).
Coronary artery spasm involves the tightening of an artery, which can deprive the heart muscle of blood and oxygen. It can be caused by emotional stress, exercise or extreme cold.
Coronary embolism occurs when a blood clot or fatty deposit travels to a coronary artery and causes a blockage.
SCAD is caused by a tear in a coronary artery. Around 80 per cent of cases occur in women, and it often happens during or soon after pregnancy.
Professor Nicholas Mills, a cardiologist at the University of Edinburgh who led the international taskforce behind the guidance, said it was “the first time that we’ve had a truly global approach to aligning how we diagnose what is probably the most important diagnosis there is”.
He said: “It kills so many people, and we’ve never got everyone together around the world to agree how we’re going to describe it, classify it, explain it to our patients.
“Our job now is to implement this as widely as possible. It’s just as relevant for the UK as it is for any other country around the world. It is a revolution. It’s going to make care better for patients.”
Mills said there had been “unintended systematic bias against women”, including through the use of the key blood test for diagnosing heart attacks at an average level, which picks up all men but misses some women.
He said: “This is used for all types of heart attack in every emergency department in the world, and we want to make sure that it’s used correctly.”
The guidance was drawn up by the ESC, the American College of Cardiology, the American Heart Association and the World Heart Federation.
KOVE Medical has raised €1.7 million to support first-in-human studies of an implantable device designed to reduce preterm birth risk after foetal surgery.
The University of Zurich spin-off is developing a device designed to close defects left by surgical instruments following fetoscopy, a minimally invasive procedure performed inside the womb.
Fetoscopies can treat life-threatening conditions before birth but require surgical instruments to pass through the uterine wall and amniotic sac.
This can weaken the protective membrane, causing fluid leakage or rupture and often leading to preterm birth.
KOVE Medical said in a statement on LinkedIn: “This is a crucial step forward for our company, and we are incredibly grateful for the strong support and trust from our syndicate of visionary angel investors.”
KOVE Medical says its device closes the defect at the end of the procedure, stabilising the membrane and preventing complications. The aim is to make in-utero interventions safe enough to become a standard method of care.
The company plans to use the seed funding to reach first-in-human studies, a key milestone for a medical device seeking regulatory approval.
The CHF1.6m round was backed by a syndicate of angel investors.
Hormonal health2 weeks agoMajor UK study could be a ‘game-changer’ for heavy periods and endometriosis
Entrepreneur6 days agoKOVE Medical raises €1.7 million to improve safety of foetal surgery
Pregnancy2 weeks agoOne week left to apply: W Accelerate with Merck KGaA and M Ventures
Pregnancy7 days agoUK study aims to transform maternity care for high-risk pregnancies
Menopause2 weeks agoQuarter of women miss work due to menstual symptoms, survey finds
Hormonal health2 weeks agoPMDD after SSRIs or hormones: Why the brain may be the missing treatment target
Diagnosis2 weeks agoArk Surgical secures further institutional backing to accelerate US expansion
Insight2 weeks agoStudy to tackle years-long delays in endometriosis diagnosis